HIGHLIGHTS
- who: Gzona Bajraktari-Sylejmani et al. from the Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg have published the Article: Evaluation of PepT1 (SLC15A1) Substrate Characteristics of Therapeutic Cyclic Peptides, in the Journal: Pharmaceutics 2022, 1610 of /2022/
- what: We established an SLC15A1 overexpressing CHO-K1 cell line suitable to investigate possible hPepT1 inhibitor and substrate characteristics.
- how: In a second step inhibition of hPepT1 by losartan one of the strongest inhibitors of this transporter was tested in both clones. The authors therefore decided to establish a cell model overexpressing SLC15A1 and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.